Alterity Therapeutics (ATHE) Cash from Financing Activities (2016 - 2019)
Alterity Therapeutics (ATHE) posted quarterly Cash from Financing Activities of $166760.3 for Q4 2019, up 62.62% year-over-year from $102549.0 in Q4 2018, and up 62.62% quarter-over-quarter from $102549.0 in Q4 2018.
Alterity Therapeutics (ATHE) Cash from Financing Activities (2016 - 2019) Analysis & Trends
Alterity Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $166760.3 for Q4 2019.
- In Q4 2019, Cash from Financing Activities rose 62.62% year-over-year to $166760.3; the TTM figure through Dec 2019 stood at $124416.7 (down 97.8% YoY), while the FY2025 annual figure was $25.4 million, up 318.28% from the prior year.
- Cash from Financing Activities for Q4 2019 stood at $166760.3, up from $102549.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $166760.3 in Q4 2019, with the low at -$115796.0 in Q4 2016.
- The 4-year median for Cash from Financing Activities is $36726.2 (2017), against an average of $31104.2.
- The sharpest annual moves came in 2018 and 2019: Cash from Financing Activities soared 452.44% in 2018, then jumped 62.62% in 2019.
- Alterity Therapeutics' Cash from Financing Activities stood at -$115796.0 in 2016, then jumped by 74.87% to -$29096.6 in 2017, then jumped by 452.44% to $102549.0 in 2018, then jumped by 62.62% to $166760.3 in 2019.
- Business Quant data shows ATHE's Cash from Financing Activities at $166760.3 in Q4 2019, $102549.0 in Q4 2018, and -$29096.6 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 166,760.26 |
| Dec 31, 2019 | 166,760.26 |
| Dec 31, 2018 | 102,548.96 |
| Dec 31, 2018 | 102,548.96 |
| Dec 31, 2017 | -29,096.57 |
| Dec 31, 2017 | -29,096.57 |
| Dec 31, 2016 | -115,795.95 |
| Dec 31, 2016 | -115,795.95 |